Thomas Kegel

673 total citations
38 papers, 398 citations indexed

About

Thomas Kegel is a scholar working on Oncology, Neurology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas Kegel has authored 38 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Neurology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas Kegel's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Research Studies (5 papers). Thomas Kegel is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Research Studies (5 papers). Thomas Kegel collaborates with scholars based in Germany, United States and South Korea. Thomas Kegel's co-authors include Hans‐Joachim Schmoll, Karin Jordan, Axel Grothey, Wieland Voigt, Hans‐Heinrich Wolf, Karin Jordan, HJ Holzhausen, Peter Helmbold, Wilfried Grothe and Michael A. Fischer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Thomas Kegel

34 papers receiving 379 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Kegel Germany 11 184 78 77 70 70 38 398
Chadi Saifan United States 13 87 0.5× 48 0.6× 71 0.9× 54 0.8× 17 0.2× 30 536
Hakan Karagöl Türkiye 12 178 1.0× 133 1.7× 123 1.6× 32 0.5× 59 0.8× 35 489
Harris Naina United States 11 122 0.7× 116 1.5× 44 0.6× 58 0.8× 39 0.6× 60 356
M. McKean United Kingdom 11 161 0.9× 143 1.8× 65 0.8× 88 1.3× 18 0.3× 14 365
Mohamed Touati Morocco 10 74 0.4× 100 1.3× 39 0.5× 78 1.1× 52 0.7× 46 316
Bertrand Lioger France 12 171 0.9× 52 0.7× 56 0.7× 72 1.0× 23 0.3× 41 513
Alberto Agazzi Italy 9 112 0.6× 50 0.6× 44 0.6× 56 0.8× 42 0.6× 19 396
Shane Y. Morita United States 9 231 1.3× 151 1.9× 169 2.2× 31 0.4× 86 1.2× 22 503
Shun C. Young United States 13 118 0.6× 116 1.5× 54 0.7× 67 1.0× 18 0.3× 18 390
Ahmet Sezer Türkiye 11 235 1.3× 77 1.0× 33 0.4× 39 0.6× 33 0.5× 48 402

Countries citing papers authored by Thomas Kegel

Since Specialization
Citations

This map shows the geographic impact of Thomas Kegel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Kegel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Kegel more than expected).

Fields of papers citing papers by Thomas Kegel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Kegel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Kegel. The network helps show where Thomas Kegel may publish in the future.

Co-authorship network of co-authors of Thomas Kegel

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Kegel. A scholar is included among the top collaborators of Thomas Kegel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Kegel. Thomas Kegel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wohlrab, Johannes, et al.. (2023). Handlungsempfehlungen zur Risikominimierung beim Einsatz von Januskinase‐Inhibitoren zur Therapie chronisch‐entzündlicher Hauterkrankungen. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 21(8). 845–852. 1 indexed citations
2.
Wohlrab, Johannes, et al.. (2023). Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 21(8). 845–851. 1 indexed citations
3.
4.
Vordermark, Dirk, et al.. (2017). Malignisierung eines Vestibularisschwannoms 13 Jahre nach Bestrahlung. HNO. 65(9). 766–770. 8 indexed citations
5.
Vordermark, Dirk, et al.. (2017). Malignization of a vestibular schwannoma 13 years after radiation therapy. HNO. 65(S2). 153–157. 8 indexed citations
6.
Jordan, Karin, Franziska Jahn, Berit Jordan, et al.. (2015). Trabectedin: Supportive care strategies and safety profile. Critical Reviews in Oncology/Hematology. 94(3). 279–290. 10 indexed citations
7.
Schmidt, Christian, Guenter Fingerle-Rowson, Angelika Boehme, et al.. (2014). Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006–2009. Leukemia & lymphoma. 56(3). 694–702. 5 indexed citations
8.
9.
Schmidt, Christian, Sebastian Fetscher, Christian Görg, et al.. (2011). Treatment of Indolent Lymphoma in Germany - Results of a Representative Population-Based Survey. Clinical Lymphoma Myeloma & Leukemia. 11(2). 204–211. 10 indexed citations
10.
11.
Jordan, Karin, H. Wolf, Wieland Voigt, et al.. (2010). Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. Bone Marrow Transplantation. 45(12). 1704–1709. 6 indexed citations
12.
Seliger, G, Lutz Peter Mueller, Thomas Kegel, et al.. (2009). Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer. International Journal of Gynecological Cancer. 19(8). 1446–1453. 12 indexed citations
13.
Petersenn, Stephan, Wieland Voigt, Thomas Kegel, et al.. (2009). Chemotherapy with Paclitaxel and Gemcitabine in Progressive Medullary and Thyroid Carcinoma of the Follicular Epithelium. Hormone and Metabolic Research. 42(1). 61–64. 12 indexed citations
14.
Jordan, Karin, et al.. (2009). 3087 The NK-1 antagonist aprepitant (APR) in combination with granisetron and dexamethasone in high dose chemotherapy (HDC). European Journal of Cancer Supplements. 7(2). 200–201. 1 indexed citations
15.
Jordan, Karin, et al.. (2008). Venous Access Ports: Frequency and Management of Complications in Oncology Patients. Onkologie. 31(7). 404–410. 26 indexed citations
16.
Voigt, Wieland, et al.. (2005). Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. Journal of Cancer Research and Clinical Oncology. 131(9). 585–590. 36 indexed citations
17.
Jordan, Karin, Axel Grothey, Wilfried Grothe, et al.. (2005). Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. European Journal Of Haematology. 74(3). 263–266. 39 indexed citations
18.
Jordan, Karin, et al.. (2005). Antiemetic Efficacy of an Oral Suspension of Granisetron plus Dexamethasone and Influence of Quality of Life on Risk for Nausea and Vomiting. Oncology Research and Treatment. 28(2). 88–92. 7 indexed citations
19.
Jordan, Karin, O Kellner, Thomas Kegel, Hans‐Joachim Schmoll, & Axel Grothey. (2004). Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers. Clinical Colorectal Cancer. 4(1). 46–50. 30 indexed citations
20.
Voigt, Wieland, Curd Behrmann, Annette J. Schlueter, et al.. (2002). A New Chemoembolization Protocol in Refractory Liver Metastasis of Colorectal Cancer – a Feasibility Study. Oncology Research and Treatment. 25(2). 158–164. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chadi Saifan Breakdown of academic impact, for papers by Hakan Karagöl Breakdown of academic impact, for papers by Harris Naina Breakdown of academic impact, for papers by M. McKean Breakdown of academic impact, for papers by Mohamed Touati Breakdown of academic impact, for papers by Bertrand Lioger Breakdown of academic impact, for papers by Alberto Agazzi Breakdown of academic impact, for papers by Shane Y. Morita Breakdown of academic impact, for papers by Shun C. Young Breakdown of academic impact, for papers by Ahmet Sezer
Rankless by CCL
2026